Medera in the News

June 13, 2025 

Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025

May 19, 2025 

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

May 12, 2025 

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

April 1, 2025 

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

March 20, 2025 

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

March 11, 2025 

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

February, 10, 2025

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

February, 7, 2025

Medera, Inc. to Participate in Two Upcoming Investor Conferences

December 18, 2024

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

December 10, 2024

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

November 19, 2024

Medera and Singapore’s Cardiovascular Disease National Collaborative Enterprise Launch Asia's First Cardiac Gene Therapy Trial for Heart Failure

October 31, 2024

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

September 24, 2024

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

September 5, 2024
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

May 6, 2024
Medera’s Sardocor Showcases Positive Interim Data from HErEF Gene Therapy Phase 1/2 Clinical Trial in Late-Breaking Oral Presentation at 27th Annual Meeting of American Society of Gene and Cell Therapy

February 28, 2024
Medera’s Sardocor Granted FDA Orphan Drug Designation for DMD-associated cardiomyopathy Gene Therapy

February 14, 2024
Medera's Sardocor announces fast track designation and dosing of 3 patients in first-in-human HFpEF gene therapy trial

December 6, 2023
Heart-in-a-jar: Singapore to bioengineer Asian mini models of failed hearts to test drugs

December 01, 2022
Medera's Sardocor announces FDA clearance of IND for first-in-human gene therapy clinical trial for DMD cardiomyopathy

November 18, 2022
Medera receives FDA clearance for first-in-human gene therapy for heart failure with preserved ejection fraction

October 27, 2022
Medera’s Novoheart partners with AstraZeneca on First Bioengineered Human Models of Heart Failure

May 12, 2020
3D-printed mini-organs may provide safe testing of COVID-19 therapies

January 6, 2020
Heart-In-A-Jar Platform Humanizing Preclinical Research